Madrigal Pharmaceuticals (MDGL) Non-Current Debt (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has 11 years of Non-Current Debt data on file, last reported at $340.3 million in Q1 2026.

• Non-Current Debt for Q1 2026 came in at $340.3 million, up 188.4% year-over-year; the trailing twelve-month figure through Mar 2026 was $340.3 million (up 188.4% YoY), and the FY2025 annual result was $339.9 million, up 189.09% from the prior year.
• Non-Current Debt steadied at $340.3 million in Q1 2026 per MDGL's latest filing, from $339.9 million in the prior quarter.
• Over five years, Non-Current Debt peaked at $340.3 million in Q1 2026 and troughed at $48.7 million in Q2 2022.
• A 5-year average of $142.8 million and a median of $116.4 million in 2024 frame the typical range for Non-Current Debt.
• On a YoY basis, Non-Current Debt climbed as much as 190.17% in 2025 and fell as far as 1.52% in 2025.
• A 5-year view of Non-Current Debt shows it stood at $49.3 million in 2022, then jumped by 134.29% to $115.5 million in 2023, then grew by 1.81% to $117.6 million in 2024, then surged by 189.09% to $339.9 million in 2025, then grew by 0.13% to $340.3 million in 2026.
• Business Quant data shows MDGL's Non-Current Debt at $340.3 million in Q1 2026, $339.9 million in Q4 2025, and $339.8 million in Q3 2025.